{
    "clinical_study": {
        "@rank": "148204", 
        "brief_summary": {
            "textblock": "RATIONALE: Some cancers become resistant to chemotherapy drugs. Combining cyclosporine with\n      chemotherapy may prevent resistance to the drugs and allow the cancer cells to be killed.\n\n      PURPOSE: Randomized phase II trial to study the effectiveness of adding cyclosporine to\n      combination chemotherapy in treating patients with relapsed or refractory acute myeloid\n      leukemia."
        }, 
        "brief_title": "Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Evaluate whether the addition of cyclosporine (CYSP) to mitoxantrone (DHAD)\n      and etoposide (VP-16) increases the response rate and duration of response in adults with\n      refractory or relapsed acute myelogenous leukemia (AML). II. Correlate response to this\n      treatment with the presence of P-glycoprotein (P-gp) multidrug resistance (MDR) and the\n      degree of in vitro modulation of leukemic blasts, including CD34+ blasts. III. Correlate\n      response with the presence of other resistance mechanisms, such as atypical MDR and non-P-gp\n      phenotype. IV. Evaluate the toxicity of this treatment in AML patients. V. Study the effect\n      of CYSP on DHAD and VP-16 pharmacokinetics and metabolism and, potentially, on intracellular\n      drug accumulation.\n\n      OUTLINE: Randomized study. The following acronyms are used: CYSP Cyclosporine, NSC-290193\n      DHAD Mitoxantrone, NSC-301739 VP-16 Etoposide, NSC-141540 Arm I: 2-Drug Combination\n      Chemotherapy. DHAD; VP-16. Arm II: 2-Drug Combination Chemotherapy with Drug Resistance\n      Inhibition. DHAD; VP-16; with CYSP.\n\n      PROJECTED ACCRUAL: At least 25 patients/arm will be entered over approximately 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Acute myelogenous leukemia (AML) in the following categories:\n        Refractory to initial standard therapy consisting of idarubicin/cytarabine and\n        amsacrin/cytarabine (on protocol HOVON 29) First or subsequent relapse following complete\n        response to standard chemotherapy (on protocols HOVON 4/4A or 11 or any other protocol) At\n        least 6 months between mitoxantrone/etoposide and relapse No myelodysplasia\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:\n        Not applicable Hepatic: Bilirubin no greater than 2 x normal Alkaline phosphatase no\n        greater than 2 x normal Renal: Creatinine no greater than 1.7 mg/dl (150 micromoles/liter)\n        OR Creatinine clearance at least 60 ml/min Cardiovascular: No uncontrolled hypertension No\n        other severe cardiac disease Pulmonary: No severe pulmonary disease Other: No known\n        intolerance to any study drug No uncontrolled severe infection Not HIV seropositive No\n        severe neurologic or metabolic disease No concomitant malignancy except: Nonmelanomatous\n        skin cancer In situ cervical carcinoma No pregnant women\n\n        PRIOR CONCURRENT THERAPY: See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002688", 
            "org_study_id": "CDR0000064413", 
            "secondary_id": [
                "DUT-KWF-CKVO-9412", 
                "EU-95003"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cyclosporine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "mitoxantrone hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Etoposide", 
                "Etoposide phosphate", 
                "Mitoxantrone"
            ]
        }, 
        "keyword": "recurrent adult acute myeloid leukemia", 
        "lastchanged_date": "December 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DUT-KWF-CKVO-9412"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels (Bruxelles)", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Cliniques Universitaires Saint-Luc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "'s-Gravenhage (Den Haag, The Hague)", 
                        "country": "Netherlands", 
                        "zip": "2545 CH"
                    }, 
                    "name": "Leyenburg Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academisch Medisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1007 MB"
                    }, 
                    "name": "Academisch Ziekenhuis der Vrije Universiteit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9713 EZ"
                    }, 
                    "name": "Academisch Ziekenhuis Groningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6202 AZ"
                    }, 
                    "name": "Academisch Ziekenhuis Maastricht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3000 CA"
                    }, 
                    "name": "University Hospital - Rotterdam Dijkzigt"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Academisch Ziekenhuis Utrecht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4031"
                    }, 
                    "name": "University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "Inselspital, Bern"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "Universitaetsspital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands", 
                "Switzerland"
            ]
        }, 
        "official_title": "AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY", 
        "overall_official": {
            "affiliation": "University Medical Centre Groningen", 
            "last_name": "Simon Daenen, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002688"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Medical Centre Groningen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1995", 
        "study_design": "Allocation: Randomized, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2007"
    }, 
    "geocoordinates": {
        "Academisch Medisch Centrum": "52.37 4.895", 
        "Academisch Ziekenhuis Groningen": "53.219 6.567", 
        "Academisch Ziekenhuis Maastricht": "50.851 5.691", 
        "Academisch Ziekenhuis Utrecht": "52.09 5.11", 
        "Academisch Ziekenhuis der Vrije Universiteit": "52.37 4.895", 
        "Cliniques Universitaires Saint-Luc": "50.85 4.352", 
        "Inselspital, Bern": "46.948 7.445", 
        "Leyenburg Ziekenhuis": "52.077 4.316", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitaetsspital": "47.369 8.539", 
        "University Hospital": "47.557 7.593", 
        "University Hospital - Rotterdam Dijkzigt": "51.924 4.482"
    }
}